Loading
A phase 2 trial of FOLFOXIRI, fOLFOX (5-FU, leucovorin, oxaliplatin), fOLFIRI (5-FU, leucovorin, irinotecan), capecitabine and other drugs in colorectal cancer, run by Yanqiao Zhang, not yet recruiting.
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation is a phase 2, interventional study registered as NCT07229846 by Yanqiao Zhang, with a registry enrolment figure of 30 participants, started 2026-02 and due to reach its primary completion in 2027-02. Interventions recorded: Aipalolitovorelizumab; XELOX + Bevacizumab; mFOLFOX + Bevacizumab; FOLFOXIRI + Bevacizumab; Oxaliplatin + Irinotecan + Capecitabine + Bevacizumab. Conditions listed: Colorectal Cancer. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: "Patients with histopathologically confirmed unresectable metastatic colorectal adenocarcinoma of MSS/pMMR type with known BRAF V600E mutation;". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag colorectal-deep-dive.
Shares FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag colorectal-deep-dive.
Shares FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/